Kura Oncology disclosed early combination data showing darlifarnib paired with Bristol Myers Squibb’s Krazati delivered response rates up to 69%, according to the company. The update frames the combination around enhancing the clinical potential of KRAS inhibitors by pairing complementary mechanisms. The announcement comes as KRAS-targeted oncology continues to expand, and companies increasingly rely on combination strategies to improve depth and durability of responses across genetically defined populations. For developers, the next checkpoint is the quality of the response across subgroups and how safety and tolerability profile compares with monotherapy. While details remain limited in the disclosure, the reported response-rate signal is likely to draw investor and partner attention as Kura and BMS evaluate the pathway toward larger registrational studies.